WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

ATC codeATC level nameNew DDDUnitAdm.routeDeadline for objection to temporary codesImplementation in ATC/DDD index
A10BX16tirzepatide1.4mgPFinal2025
A16AB25olipudase alfa15mgPFinal2025
B03XA08vadadustat0.3gOFinal2025
C01EB24mavacamten5mgO01.09.20242025
G02CX06fezolinetant45mgO01.09.20242025
J05AX24 tecovirimat0.4gPFinal2025
J05AX33labuvirtide45.7mgP01.09.20242025
L04AC24mirikizumab7.1mgPFinal2025
L04AF07 1)deucravacitinib6mgOFinal2025
L04AF08ritlecitinib50mgO01.09.20242025
L04AJ04 2)sutimlimab0.46gPFinal2025
M01AE20pelubiprofen90mgO01.09.20242025
N02CD07atogepant60mgO01.09.20242025
R03DX11tezepelumab7.5mgPFinal2025
R06AA02diphenhydramine0.2gPFinal2025
1) ATC code altered from L04AA56, valid from January 2024
2) ATC code altered from L04AA55, valid from January 2024

Last updated: 2024-05-07